SAO PAULO, March 21 (Reuters) - Brazilian drugmaker Hypera (HYPE3.SA), opens new tab plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's (NOVOb.CO), ...

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone ...

Hypera SA (HYPMY) recently announced a dividend of $0.06 per share, payable on a date yet to be confirmed, with the ex-dividend date set for October 5, 2023. As investors eagerly anticipate this ...

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

SAO PAULO, Oct 24 (Reuters) - The board of directors of Brazil's pharmaceutical company Hypera (HYPE3.SA), opens new tab has unanimously decided to reject rival EMS's offer to merge, it said on ...

Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have ...

Brazilian pharmaceutical company Hypera has discussed a takeover offer from rival company NC Group, the owner of EMS SA, but talks are not currently active, one source with knowledge of the matter ...

Hypera Pharma, along with all Rimini Street clients, benefits from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) ...

Brazilian pharmaceutical company Hypera said on Thursday it expects 1.7 billion reais ($331.83 million) in net income for 2022. The company also said it sees its 2022 adjusted earnings before interest ...